Universal Beteiligungs und Servicegesellschaft mbH Sells 8,333 Shares of Biogen Inc. $BIIB

Universal Beteiligungs und Servicegesellschaft mbH reduced its position in Biogen Inc. (NASDAQ:BIIB) by 5.3% during the second quarter, Holdings Channel reports. The institutional investor owned 149,128 shares of the biotechnology company’s stock after selling 8,333 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Biogen were worth $18,729,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Integrated Quantitative Investments LLC raised its stake in shares of Biogen by 8.5% during the 2nd quarter. Integrated Quantitative Investments LLC now owns 2,820 shares of the biotechnology company’s stock worth $354,000 after acquiring an additional 220 shares in the last quarter. Financial Gravity Companies Inc. purchased a new position in Biogen in the second quarter worth $37,000. Summitry LLC acquired a new position in shares of Biogen during the second quarter worth $333,000. Letko Brosseau & Associates Inc. increased its position in shares of Biogen by 1.8% during the second quarter. Letko Brosseau & Associates Inc. now owns 117,655 shares of the biotechnology company’s stock worth $14,776,000 after purchasing an additional 2,045 shares in the last quarter. Finally, Citizens Financial Group Inc. RI purchased a new stake in shares of Biogen during the 2nd quarter valued at $225,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

BIIB has been the topic of several research analyst reports. Morgan Stanley boosted their target price on Biogen from $144.00 to $149.00 and gave the stock an “equal weight” rating in a research note on Friday, October 10th. Piper Sandler raised their price target on Biogen from $115.00 to $118.00 and gave the stock a “neutral” rating in a report on Friday, September 12th. Royal Bank Of Canada dropped their price target on Biogen from $217.00 to $210.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Mizuho upped their price objective on shares of Biogen from $169.00 to $177.00 and gave the company an “outperform” rating in a report on Monday, November 3rd. Finally, Stifel Nicolaus raised shares of Biogen from a “hold” rating to a “buy” rating and increased their price objective for the company from $144.00 to $202.00 in a research report on Thursday, November 6th. Ten investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $177.46.

Insider Buying and Selling

In other news, insider Priya Singhal sold 517 shares of the company’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total value of $69,045.35. Following the sale, the insider directly owned 5,772 shares of the company’s stock, valued at $770,850.60. This represents a 8.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.18% of the company’s stock.

Biogen Stock Up 2.5%

Shares of BIIB stock opened at $168.83 on Wednesday. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $170.78. The firm has a market capitalization of $24.77 billion, a PE ratio of 16.14, a P/E/G ratio of 1.17 and a beta of 0.10. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.79 and a current ratio of 2.50. The stock’s 50-day simple moving average is $149.34 and its 200-day simple moving average is $137.12.

Biogen (NASDAQ:BIIB) last released its earnings results on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, topping analysts’ consensus estimates of $3.89 by $0.92. The firm had revenue of $2.53 billion during the quarter, compared to the consensus estimate of $2.34 billion. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The company’s revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.08 earnings per share. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. Equities analysts expect that Biogen Inc. will post 15.83 earnings per share for the current year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.